Identification alpha-2-HS-glycoprotein precursor and tubulin beta chain as serology diagnosis biomarker of colorectal cancer

Diagnostic Pathology

Chun-Fang Gao²  Hong-Mei Chen³  Yan Liu⁴  Ming Li⁵  Xue-Yan Ge²  Rui Kang²  Nai-Jun Fan¹ 

[1] The General Hospital of Jinan Military Region, Jinan, China;Institute of Anal-colorectal Surgery, No.150 Central Hospital of PLA, Luoyang, RP China;Clinical Laboratory, The First People’s Hospital of the City of Luoyang, Luoyang, RP China;Neuro- Surgery Department, No.150 Central Hospital of PLA, Luoyang, RP China;Respiration Department, No.150 Central Hospital of PLA, Luoyang, RP China

关键词: Tubulin beta chain;    Alpha-2-HS-glycoprotein;    Proteomics;    Biological markers;    Diagnosis;    Colorectal neoplasms;   

Others  :  867886
DOI  :  10.1186/1746-1596-9-53

 received in 2013-09-23, accepted in 2014-03-05,  发布年份 2014

【 摘 要 】

Background

Colorectal cancer (CRC) remains a major worldwide cause of cancer-related morbidity and mortality largely due to the insidious onset of the disease. The current clinical procedures utilized for disease diagnosis are invasive, unpleasant, and inconvenient. Hence, the need for simple blood tests that could be used for the early detection is crucial for its ultimate control and prevention.

Methods

The present work is a case–control study focused on proteomic analysis of serum of healthy volunteers and CRC patients by the ClinProt profiling technology based on mass spectrometry. This approach allowed to identifying a pattern of proteins/peptides able to differentiate the studied populations. Moreover, some of peptides differentially expressed in the serum of patients as compared to healthy volunteers were identified by LTQ Orbitrap XL.

Results

A Quick Classifier Algorithm was used to construct the peptidome patterns (m/z 1208, 1467, 1505, 1618, 1656 and 4215) for the identification of CRC from healthy volunteers with accuracy close to 100% (>CEA, P < 0.05). Peaks at m/z 1505 and 1618 were identified as alpha-2-HS-glycoprotein precursor and tubulin beta chain, respectively.

Conclusions

Alpha-2-HS-glycoprotein precursor and tubulin beta chain could be involved in the pathogenesis of CRC and perform as potential serology diagnosis biomarker.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/4796578761089186 webcite.

【 授权许可】

   
2014 Fan et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
• [3]Ciccolallo L, Capocaccia R, Coleman MP, Berrino F, Coebergh JW, Damhuis RA, Faivre J, Martinez-Garcia C, Moller H, Ponz de Leon M, Launoy G, Raverdy N, Williams EM, Gatta G: Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut 2005, 54:268-273.
• [4]Engwegen JY, Helgason HH, Cats A, Harris N, Bonfrer JM, Schellens JH, Beijnen JH: Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 2006, 12:1536-1544.
• [5]Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, Van Ballegooijen M, Goede SL, Ries LA: Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116:544-573.
• [6]Smith RA, Cokkinides V, Brooks D, Saslow D, Shah M, Brawley OW: Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2011, 61:8-30.
• [7]Ang CS, Phung J, Nice EC: The discovery and validation of colorectal cancer biomarkers. Biomed Chromatogr 2011, 25:82-99.
• [8]Ahlquist DA: Molecular detection of colorectal neoplasia. Gastroenterology 2010, 138:2127-2139.
• [9]Yatabe J, Yatabe MS, Ishibashi K, Nozawa Y, Sanada H: Early detection of colon cancer by amino acid profiling using AminoIndex technology: a case report. Diagn Pathol 2013, 8:203. BioMed Central Full Text
• [10]Chen C, Wang L, Liao Q, Huang Y, Ye H, Chen F, Xu L, Ye M, Duan S: Hypermethylation of EDNRB promoter contributes to the risk of colorectal cancer. Diagn Pathol 2013, 8:199. BioMed Central Full Text
• [11]Fletcher RH: Carcinoembryonic antigen. Ann Intern Med 1986, 104:66-73.
• [12]Wulfkuhle JD, Liotta LA, Petricoin EF: Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003, 3:267-275.
• [13]Issaq HJ, Xiao Z, Veenstra TD: Serum and plasma proteomics. Chem Rev 2007, 107:3601-3620.
• [14]Pan C, He N, Zhao M, Gu Y, Huang Z, Li W, Xia Y, Wu P: Subdividing the M1 stage of liver metastasis for nasopharyngeal carcinoma to better predict metastatic survival. Med Oncol 2011, 28:1349-1355.
• [15]Fan NJ, Gao CF, Zhao G, Wang XL, Qiao L: Serum peptidome patterns for early screening of esophageal squamous cell carcinoma. Biotechnol Appl Biochem 2012, 59:276-282.
• [16]Fan NJ, Gao CF, Zhao G, Wang XL, Liu QY: Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis. Diagn Pathol 2012, 7:45. BioMed Central Full Text
• [17]Fan NJ, Gao CF, Wang XL: Identification of regional lymph node involvement of colorectal cancer by serum SELDI proteomic patterns. Gastroenterol Res Pract 2011, 2011:784967.
• [18]West-Norager M, Kelstrup CD, Schou C, Hogdall EV, Hogdall CK, Heegaard NH: Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 847:30-37.
• [19]Shin S, Cazares L, Schneider H, Mitchell S, Laronga C, Semmes OJ, Perry RR, Drake RR: Serum biomarkers to differentiate benign and malignant mammographic lesions. J Am Coll Surg 2007, 204:1065-1071. discussion 1071–1063
• [20]Baumann S, Ceglarek U, Fiedler GM, Lembcke J, Leichtle A, Thiery J: Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2005, 51:973-980.
• [21]Huang YJ, Xuan C, Zhang BB, Liao M, Deng KF, He M, Zhao JM: SELDI-TOF MS profiling of serum for detection of nasopharyngeal carcinoma. J Exp Clin Cancer Res 2009, 28:85. BioMed Central Full Text
• [22]Yao N, Chen H, Lin H, Deng C, Zhang X: Enrichment of peptides in serum by C(8)-functionalized magnetic nanoparticles for direct matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis. J Chromatogr A 2008, 1185:93-101.
• [23]Whiteaker JR, Zhao L, Zhang HY, Feng LC, Piening BD, Anderson L, Paulovich AG: Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem 2007, 362:44-54.
• [24]Fan NJ, Gao CF, Wang XL, Zhao G, Liu QY, Zhang YY, Cheng BG: Serum peptidome patterns of colorectal cancer based on magnetic bead separation and maldi-tof mass spectrometry analysis. J Biomed Biotechnol 2012, 2012:985020.
• [25]Tang W, Shi YQ, Zou JJ, Chen XF, Zheng JY, Zhao SW, Liu ZM: Serum biomarker of diabetic peripheral neuropathy indentified by differential proteomics. Front Biosci 2011, 16:2671-2681.
• [26]Compton CC, Greene FL: The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004, 54:295-308.
• [27]Ketterlinus R, Hsieh SY, Teng SH, Lee H, Pusch W: Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. Biotechniques 2005, suppl:37-40.
• [28]Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlov J: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116.
• [29]Liu Y, Tang W, Wang J, Xie L, Li T, He Y, Qin X, Li S: Clinicopathological and prognostic significance of S100A4 overexpression in colorectal cancer: a meta-analysis. Diagn Pathol 2013, 8:181. BioMed Central Full Text
• [30]Wangefjord S, Brandstedt J, Lindquist KE, Nodin B, Jirstrom K, Eberhard J: Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer. Diagn Pathol 2013, 8:10. BioMed Central Full Text
• [31]Stulik J, Hernychova L, Porkertova S, Knizek J, Macela A, Bures J, Jandik P, Langridge JI, Jungblut PR: Proteome study of colorectal carcinogenesis. Electrophoresis 2001, 22:3019-3025.
• [32]Rho JH, Qin S, Wang JY, Roehrl MH: Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J Proteome Res 2008, 7:2959-2972.
• [33]Alfonso P, Nunez A, Madoz-Gurpide J, Lombardia L, Sanchez L, Casal JI: Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics 2005, 5:2602-2611.
• [34]Kim HJ, Kang HJ, Lee H, Lee ST, Yu MH, Kim H, Lee C: Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res 2009, 8:1368-1379.
• [35]Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, Coffey RJ, Caprioli RM: Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004, 4:793-811.
• [36]Fan NJ, Gao CF, Wang CS, Lv JJ, Zhao G, Sheng XH, Wang XL, Li DH, Liu QY, Yin J: Discovery and verification of gelsolin as a potential biomarker of colorectal adenocarcinoma in the Chinese population: examining differential protein expression using an iTRAQ labelling-based proteomics approach. Can J Gastroenterol 2012, 26:41-47.
• [37]Hudler P, Gorsic M, Komel R: Proteomic strategies and challenges in tumor metastasis research. Clin Exp Metastasis 2010, 27:441-451.
• [38]Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A: Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006, 94:1898-1905.
• [39]Liu XP, Shen J, Li ZF, Yan L, Gu J: A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest 2006, 24:747-753.
• [40]Ward DG, Nyangoma S, Joy H, Hamilton E, Wei W, Tselepis C, Steven N, Wakelam MJ, Johnson PJ, Ismail T, Martin A: Proteomic profiling of urine for the detection of colon cancer. Proc Natl Acad Sci U S A 2008, 6:19.
• [41]Wang Q, Shen J, Li ZF, Jie JZ, Wang WY, Wang J, Zhang ZT, Li ZX, Yan L, Gu J: Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer 2009, 9:287. BioMed Central Full Text
• [42]Cairns DA, Barrett JH, Billingham LJ, Stanley AJ, Xinarianos G, Field JK, Johnson PJ, Selby PJ, Banks RE: Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison. Proteomics 2009, 9:74-86.
• [43]Swets JA: Measuring the accuracy of diagnostic systems. Science 1988, 240:1285-1293.
• [44]Kornfeld R, Kornfeld S: Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 1985, 54:631-664.
• [45]Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnen-Dechent W: Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J 2003, 376:135-145.
• [46]Triffitt JT, Gebauer U, Ashton BA, Owen ME, Reynolds JJ: Origin of plasma alpha2HS-glycoprotein and its accumulation in bone. Nature 1976, 262:226-227.
• [47]Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, Jahnen-Dechent W, Shanahan CM: Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005, 16:2920-2930.
• [48]Sakwe AM, Koumangoye R, Goodwin SJ, Ochieng J: Fetuin-A ({alpha}2HS-glycoprotein) is a major serum adhesive protein that mediates growth signaling in breast tumor cells. J Biol Chem 2010, 285:41827-41835.
• [49]Yi JK, Chang JW, Han W, Lee JW, Ko E, Kim DH, Bae JY, Yu J, Lee C, Yu MH, Noh DY: Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis. Cancer Epidemiol Biomarkers Prev 2009, 18:1357-1364.
• [50]Maxwell F, McGlynn LM, Muir HC, Talwar D, Benzeval M, Robertson T, Roxburgh CS, McMillan DC, Horgan PG, Shiels PG: Telomere attrition and decreased fetuin-A levels indicate accelerated biological aging and are implicated in the pathogenesis of colorectal cancer. Clin Cancer Res 2011, 17:5573-5581.
• [51]Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, Kiernan I, O’Byrne KJ, Kennedy MJ, Lynch V, Clynes M: Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer 2012, 131:911-923.
• [52]Cottingham K: Candidate biomarkers for liver cancer. J Proteome Res 2009, 8:428.
• [53]Comunale MA, Wang M, Hafner J, Krakover J, Rodemich L, Kopenhaver B, Long RE, Junaidi O, Bisceglie AM, Block TM, Mehta AS: Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res 2009, 8:595-602.
• [54]Suarez Nieto C, Cuesta Garcia A, Fernandez Bustillo E, Mendez Colunga JC, Alvarez Marcos C: Serum glycoproteins and prognosis in cancer of the head and neck. Clin Otolaryngol Allied Sci 1986, 11:41-45.
• [55]Swallow CJ, Partridge EA, Macmillan JC, Tajirian T, DiGuglielmo GM, Hay K, Szweras M, Jahnen-Dechent W, Wrana JL, Redston M, Gallinger S, Dennis JW: alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression. Cancer Res 2004, 64:6402-6409.
• [56]Quaresima B, Crugliano T, Gaspari M, Faniello MC, Cosimo P, Valanzano R, Genuardi M, Cannataro M, Veltri P, Baudi F, Doldo P, Cuda G, Venuta S, Costanzo F: A proteomics approach to identify changes in protein profiles in serum of Familial Adenomatous Polyposis patients. Cancer Lett 2008, 272:40-52.
• [57]Yeh IT, Luduena RF: The betaII isotype of tubulin is present in the cell nuclei of a variety of cancers. Cell Motil Cytoskeleton 2004, 57:96-106.
• [58]Bryan J, Wilson L: Are cytoplasmic microtubules heteropolymers? Proc Natl Acad Sci U S A 1971, 68:1762-1766.
• [59]Perez EA: Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009, 8:2086-2095.
• [60]Dumontet C, Jordan MA: Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010, 9:790-803.
• [61]Kavallaris M: Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010, 10:194-204.
• [62]Mariani M, Zannoni GF, Sioletic S, Sieber S, Martino C, Martinelli E, Coco C, Scambia G, Shahabi S, Ferlini C: Gender influences the class III and V beta-tubulin ability to predict poor outcome in colorectal cancer. Clin Cancer Res 2012, 18:2964-2975.
• [63]Bouras G, Nakanishi T, Fujita Y, Tsunemi S, Takubo T, Tanigawa N: Identification of beta-tubulin as a common immunogen in gastrointestinal malignancy by mass spectrometry of colorectal cancer proteome: implications for early disease detection. Anal Bioanal Chem 2012, 403:1801-1809.